- Conditions
- Congenital Heart Disease
- Interventions
- Tranexamic Acid, Acute Normovolemic Hemodilution
- Drug · Procedure
- Lead sponsor
- Aymen N Naguib
- Other
- Eligibility
- Up to 28 Days
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 445
matching trials from the live ClinicalTrials.gov search.
- Conditions
- COVID-19, Respiratory Failure, ARDS
- Interventions
- Tenecteplase, Placebo
- Drug
- Lead sponsor
- Hooman Poor
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Deep Venous Thrombosis
- Interventions
- Desirudin (Iprivask™), Heparin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Brain Injury, Venous Thrombosis
- Interventions
- Enoxaparin
- Drug
- Lead sponsor
- Hennepin Healthcare Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Deep Venous Thrombosis, Post Thrombotic Syndrome
- Interventions
- Catheter directed thrombolysis plus anticoagulation, Anticoagulation
- Combination Product · Drug
- Lead sponsor
- University of Toledo Health Science Campus
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Toledo, Ohio
- Conditions
- Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- enoxaparin, heparin
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 1999
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Evanston, Illinois
- Conditions
- TBI (Traumatic Brain Injury), VTE (Venous Thromboembolism)
- Interventions
- Enoxaparin Sodium 150 MG/ML Prefilled Syringe, Heparin
- Drug
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Cholangiocarcinoma, Liver Neoplasms
- Interventions
- Floxuridine, Dexamethasone, Gemcitabine, Oxaliplatin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Antithrombotic
- Interventions
- Enoxaparin, unfractionated heparin (UFH), BMS-986177
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 3
- States / cities
- Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota
- Conditions
- Cancer Patients First-ever Acute Ischemic Stroke
- Interventions
- Enoxaparin, Aspirin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
- Conditions
- Venous Thromboembolism
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Rivaroxaban placebo, Enoxaparin placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 8,101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more
- Conditions
- Interstitial Cystitis, Bladder Pain Syndrome
- Interventions
- VNX001, Placebo, Lidocaine, Heparin
- Drug
- Lead sponsor
- Vaneltix Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Escondido, California • Los Angeles, California • Newport Beach, California + 10 more
- Conditions
- Coronary Disease
- Interventions
- Otamixaban (XRP0673), unfractionated heparin, eptifibatide
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Venous Thromboembolism
- Interventions
- dalteparin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 17
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more
- Conditions
- Thrombophilia Due to Acquired Antithrombin III Deficiency
- Interventions
- Recombinant antithrombin (rhAT)
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Venous Thromboembolism, Pulmonary Embolism
- Interventions
- VTE prophylaxis with Enoxaparin 30mg BID, VTE prophylaxis with Aspirin 81mg BID
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- End-stage Renal Disease
- Interventions
- PROPATEN, Standard Graft
- Device
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • New Orleans, Louisiana • Cleveland, Ohio + 1 more
- Conditions
- Venous Thromboembolism, Thromboprophylaxis, Trauma
- Interventions
- Aspirin, Enoxaparin
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Thromboembolism
- Interventions
- Enoxaparin
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Venous Thrombosis
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Active comparator, Rivaroxaban (BAY59-7939) suspension
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Orange, California + 10 more
- Conditions
- Cataract
- Interventions
- CT LUCIA 621P
- Device
- Lead sponsor
- Carl Zeiss Meditec AG
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Lexington, Kentucky • Hershey, Pennsylvania
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- Nab paclitaxel, Gemcitabine, Dociparstat
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Burbank, California • Greenbrae, California + 12 more
- Conditions
- Thrombocytopenia
- Interventions
- Not listed
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- 6 Months and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 21
- States / cities
- Atlanta, Georgia • Iowa City, Iowa • New Orleans, Louisiana + 13 more
- Conditions
- Hemodialysis Catheter-related Bacteremia
- Interventions
- tigecycline, N-acetylcysteine, heparin combination, guide-wire exchange
- Drug · Device
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- San Diego, California